Thousands to test new migraine meds in largest Real-Life study

NCT ID NCT07103694

Recruiting now Disease control Sponsor: IRCCS San Raffaele Roma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 2,641 people with episodic or chronic migraine to see how well newer drugs—like monoclonal antibodies, gepants, ditans, and a sumatriptan-naproxen combo—work in everyday life. Researchers will track monthly migraine days, pain relief within 2 hours, and any side effects. The goal is to understand real-world effectiveness and safety beyond controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPISODIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Disorders, Secondary migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE EPISODIC MIGRAINE MEDICATION OVERUSE HEADACHE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

IRCCS San Raffaele
RECRUITING

Rome, Italy, 00163, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Istituto Auxologico Italiano IRCCS
RECRUITING

Milan, Italy, 20145, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••